Share Name Share Symbol Market Type Share ISIN Share Description
Wilmington Plc LSE:WIL London Ordinary Share GB0009692319 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  3.00 1.45% 210.00 30,173 16:35:05
Bid Price Offer Price High Price Low Price Open Price
206.00 214.00 208.00 208.00 208.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 113.08 6.43 5.33 39.4 184
Last Trade Time Trade Type Trade Size Trade Price Currency
14:42:05 O 10,173 208.00 GBX

Wilmington (WIL) Latest News

More Wilmington News
Wilmington Investors    Wilmington Takeover Rumours

Wilmington (WIL) Discussions and Chat

Wilmington (WIL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Wilmington trades in real-time

Wilmington (WIL) Top Chat Posts

Wilmington Daily Update: Wilmington Plc is listed in the Media sector of the London Stock Exchange with ticker WIL. The last closing price for Wilmington was 207p.
Wilmington Plc has a 4 week average price of 191p and a 12 week average price of 191p.
The 1 year high share price is 208p while the 1 year low share price is currently 117p.
There are currently 87,559,306 shares in issue and the average daily traded volume is 148,948 shares. The market capitalisation of Wilmington Plc is £183,874,542.60.
sphere25: Some stand out exchanges here today and someone has come in to bid for 50k at 200p (currently sat on the bid with 49999 left to fill on the book). Chart looks interesting IF it breaks out. WIL going to break out on heavy volume? All imo DYOR
sphere25: 250k buy print at 190p just now. Someone is keen - significant chunk for quiet ole WIL. Is it breakout time? All imo DYOR UPDATE: Unless that's a glitch, two further identical 250k buys at the same time as the one above but odd small lag in updating on the book. FURTHER UPDATE: Price has broken out with a sharp move higher up to 202p. Double checked the two additional 250k buy prints and it was an error with an inadvertent additional 250k buy print then being corrected by another 250k print (i.e. - 250k) though ADVFN doesn't show corrections.
sphere25: Price currently 182p. I'm quietly nibbling away at these price levels ssshhhh. It is illiquid this so not too many. It is still hard to buy without moving the price atm, but managing to grab a few when they come available as there is pretty much zero interest here, which is always a good sign! I think this will comfortably head back over £2. All imo DYOR
sphere25: So we're in reporting season now so a barrage of results will follow, particularly as we get into March. I don't imagine there being too many where investors will look at the results and next years earnings (or indeed the year after) and smell value. Some of the moves on results already have been rather muted. Noted WIL today looking interesting and had a high level look in. Price hasn't recovered a great deal from pre-covid highs and they have managed to turn in a resilient revenue performance, profits actually higher than last year and dividend reinstated. £157m market cap at 179p and net debt of £23m so an EV of £180m. Net cash generated from operating activities £7m with FCF of £4.1m in the interims today. Last year the full year respective cash flow figures were £20.2m and £14.3m. Pre-covid, the market was happy to sit at a valuation at around that 250p mark so a market cap of £220m. The question is: Is the market being too bearish here and has the recovery been priced in? If they can turn out such a resilient performance like this in such a difficult environment, what happens when the shackles are off? Price is currently testing key resistance on the chart, but the spread on this one doesn't make it conducive to trading. Large gaps in the mornings at times too as orders take time to fill. Much more than a short term contender? All imo DYOR
opodio: CEO leaves ahead of results. They be good? Bad? Wilmington plc (LSE: WIL), the provider of information, education and networking services in Risk & Compliance, Professional and Healthcare knowledge areas, announces that Pedro Ros has informed the Board of his intention to step down from his position as Chief Executive Officer of the Company. The Board has agreed with Pedro that he will step down from the Board on 13 February 2019 and will be available over the following months to ensure a smooth and orderly handover. Martin Morgan, Chairman, will act as Executive Chairman from 13 February until Pedro’s replacement is appointed. The Board will initiate a search for a new Chief Executive Officer and an update will be made in due course. As previously advised, the Company will announce its half year results for the period to 31 December 2018 on Thursday 21 February 2019.
ppreston1: Mixed results. However appointment of Martin Morgan as Chairman is a positive development and removes uncertainty about the leadership of the company. He has a lot of experience in the digital arena which will definitely help to drive WIL's digital strategy. I expect the share price to pick up later today.
ppreston1: At last the share price is beginning to wake up. Nice double bottom also formed on the chart.
ppreston1: Another director buy announced today, yet share price continues to slide. This must be attracting some bid interest on a forward P/E of 10x.
woodcutter: taken a position in WIL strong director buying and very cash generative. could benefit from the digital revolution and heavy compliance struture now in global business. woody
cockneyrebel: Acquisition: RNS Number : 4228X Wilmington Group Plc 07 February 2013 7 February 2013 Wilmington Group plc Acquisition of NHiS Ltd further strengthens Wilmington's presence in the healthcare market Wilmington Group plc, the provider of Information, Compliance, and Education to professional markets announces the acquisition of the entire issued and to be issued share capital of NHiS Limited ("the Business") for an initial cash consideration of GBP5.6m and a further deferred consideration of up to GBP3.75m subject to the Business achieving challenging targets for the growth in underlying profit. The deferred consideration will be satisfied by issuing of up to 1.5m new Wilmington Group plc shares in October 2016 dependent inter alia upon NHiS's audited future earnings for the years ended 30(th) June 2015 and 30(th) June 2016. The number of new Wilmington Group plc shares to be issued in October 2016 will be determined by reference to the average of the closing mid market price on the preceding five business days. The Business was acquired with cash of GBP0.6m and the initial consideration will be financed out of the Group's existing GBP65m debt facility. NHiS has been in operation since 2007 and is a leading provider of business intelligence, data analysis, workflow tools and other services to pharmaceutical companies in the UK. Around 40% of its revenue is derived from subscriptions and the business has enjoyed high overall renewal rates as defined by customer spend in excess of 90%. Over 75% of NHiS revenue is delivered digitally. The acquisition of NHiS is consistent with Wilmington's strategy of acquiring businesses with high repeat revenues and strong, cash generative income streams in the Group's key market verticals. The Business will form part of the Wilmington Healthcare Division and will work closely with the highly complementary Binley's Healthcare Information business. The existing executive management team led by Nick Merryfield, the founding Managing Director, and Paul Midgley will remain with the business and they, along with five other individuals, comprise the vendors of the Business. NHiS's last annual results to March 2012*, showed revenue of GBP1.8m, up 45% from the prior year and profits before tax and nonrecurring costs of GBP0.8m. The Business has seen a strong start to the year and turnover for the first nine months increased by 20%. Deferred income as 31(st) December 2012 was up 50% on 31(st) December 2011. Gross Assets at 31(st) March 2012 were GBP1.6m. The acquisition is expected to be earnings enhancing in the first full year of ownership. *unaudited accounts adjusted for Wilmington Group plc accounting policies Commenting on the acquisition Charlie Brady, Chief Executive of Wilmington Group, said: "NHiS is an innovative business that has built up a major business intelligence and technology capability in a complementary area where our own Binleys Healthcare Information continues to see good growth potential. The Business will benefit from being part of a larger group with the infrastructure and resources of Binleys. We are particularly pleased that the existing highly experienced management team are joining the Wilmington Group and look forward to working with them as they continue to develop NHiS".
Wilmington share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210622 20:55:16